ArticleInternational journal of women's health2025
Understanding Preferences, Needs, and Expectations for Pharmaceutical Treatment of Symptomatic Uterine Fibroids Based on Surveys of Healthcare Providers and Patients.
Article in International journal of women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Limited evidence is available regarding preferences of women with uterine fibroids (UF) and treating healthcare providers (HCPs) regarding treatment attributes; this evidence could contribute to patient-centered shared decision-making. The aim of this study was to understand HCP and patient preferences when evaluating pharmaceutical treatments for symptomatic UF, and to identify HCP and patient segments that differ in their preferences. Methods: HCPs involved in UF management and patients diagnosed with UF completed a survey assessing the importance of treatment attributes in the UF therapy choice; an adaptive self-explication method was applied to estimate relative importance (RI), indexed to an average of 100. Attributes with RI >100 or <100 indicated a larger or lesser influence, respectively, in driving treatment choice. A clustering (K-means) algorithm was used to determine HCP and patient segments. Attribute RI was estimated for the overall sample and segments. Segment-specific RI estimates that were >10 points higher or lower than the overall study population mean were considered key differentiating drivers for that segment. Results: In total, 375 HCPs and 300 patients responded to the survey. Four HCP and four patient segments were identified. Healthcare provider segments identified were: "efficacy-focused" (n=99), "safety-focused" (n=97), "convenience-focused" (n=93), and "economics-focused" (n=86). Patient segments identified were: "symptom-relief-driven" (n=127), "information-driven" (n=67), "cost-sensitive and surgery-averse" (n=58), and "risk-averse" (n=48). Conclusion: HCPs and patients consider a variety of factors when assessing uterine fibroid treatments. For HCPs, segmentation may elucidate motivations behind treatment choices, while segmentation of patients into distinct groups, each with specific needs, goals, and behaviors, allows for more tailored care. Understanding treatment decision drivers can support patient-centered shared decision-making by enabling HCPs to recognize patient segments and engage with patients accordingly. Shared decision-making may help optimize UF management by focusing discussions on patients' priorities, increasing patient engagement, and improving health equity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.